Highest-materiality recent filing
Edesa Biotech announces $3.5M PIPE led by CEO; funds vitiligo program
Gross proceeds ~$3.5M from sale of 729,241 common shares to healthcare-focused investors and CEO.
Edesa Biotech: paridiprubart shows 32% relative mortality reduction in AKI/ARDS patients
Exploratory Phase 3 data: paridiprubart + SOC reduced 28-day mortality to 33% vs 49% placebo (p<0.005).
Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints
Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright
ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.
Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2
Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement
Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board
Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.
Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital
Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment
CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.
Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study
Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial
Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug
Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.
Edesa Biotech FY2023 net loss $8.4M ($2.93/sh); secures C$23M govt funding for Phase 3 ARDS trial
Net loss narrowed to $8.4M ($2.93 per share) from $17.6M ($8.37) in FY2022; R&D expenses fell to $4.8M from $13.3M.
Edesa Biotech regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq letter confirming compliance with minimum bid price of $1.00/share after 10 consecutive business days.
Edesa Biotech secures $10M revolving credit facility from CEO; $3.5M available, matures March 2026
Revolving credit facility of up to $10M from Pardeep Nijhawan Medicine Professional Corp., controlled by CEO.
Government of Canada commits up to C$23M (US$17M) for Phase 3 study of EB05 (paridiprubart) in ARDS; C$5.75M non-repayable.
Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive
Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).
Edesa Biotech receives Nasdaq deficiency letter for bid price below $1, has 180 days to cure
Company has until Dec 19, 2023 to regain compliance by closing at $1 or more for 10 consecutive business days.
Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug
Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.
Edesa Biotech enters ATM equity distribution agreement for up to $20M (current capacity $8.37M)
Up to $20M aggregate offering price; currently limited to ~$8.37M under S-3 rules.
Edesa Biotech reports Q1 net loss of $2.33M; FDA Fast Track for ARDS drug
Net loss narrowed to $2.33M ($0.13/sh) from $4.38M ($0.33) in prior-year quarter.
Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive
Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.
Edesa Biotech closes $3.0M private placement priced at $1.125 per share
Sold 2,691,337 common shares with warrants to purchase up to 1,345,665 shares each (12-month $1.00 and 3-year $1.50 exercise).
Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing
Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.
Edesa Biotech raises $10M in registered direct offering at $3.65/share
Gross proceeds of $10.0M from sale of 2,739,727 common shares or equivalents at $3.65/share.
the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025
Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.
the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors
Edesa Biotech, Inc. (the “Company”) has appointed Stephen Lemieux (age 47) as our Chief Financial Officer pursuant to an employment agreement.
On May 23, 2023, Kathi Niffenegger, the Chief Financial Officer of the Company, notified the Company of her intention to retire from her position and responsibilities as Chief Financial Officer effective July 15, 2023.
the Board voted to appoint Jennifer Chao as a director of the Company to fill a vacancy on the Board
On February 28, 2022, Peter van der Velden notified the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”) of his decision to resign from the Board and its committees, effective as of February 28, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material